HMOX1 and non-small cell lung carcinoma: The antimalarial drug dihydroartemisinin (DHA) reduces the expression of HO-1 in osimertinib-resistant NSCLC cells, inhibiting cell proliferation and cooperating with osimertinib to improve ROS levels and reverse the resistance of NSCLC to osimertinib [86].